Mysoline
(Primidone)PreclinicalSmall molecule
Mysoline is one of 36 small molecule programs targeting Essential Tremor. It is currently in Preclinical.
1
Indications
5
Total Trials
0
Active Trials
35
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
46 competitors in Essential Tremor
#DrugCompanyPhaseTrials
1Namenda
AbbVieApproved
Epidiolex
Jazz PharmaceuticalsApproved
Marinol
Alnylam PharmaceuticalsApproved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Topamax
WWim Janssens
Approved
Mirapex
Boehringer IngelheimPhase 3
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Xyrem
Jazz PharmaceuticalsPhase 2
Zonegran
AAzurity Pharmaceuticals
Phase 2
Fycompa
CCatalyst Biosciences
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Essential Tremor1 trial
Fasting Conditions1 trial
Bioequivalence Study of Primidone Tablets 50 mg of Dr. Reddy's Under Fasting Conditions
Completed·—·Phase 1·NCT01132040·24 enrolled
Clopidogrel1 trial
Effect of Primidone on Platelet Responsiveness in Patients Determined to be Clopidogrel Resistant
Withdrawn·—·Phase 2·NCT02008123
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
MYSOLINE
NDA NDA009170
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Primidone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- VValeant Pharmaceuticals